Neo/Adjuvant Immunotherapy in Resectable Melanoma: Implementing Novel and Emerging Strategies to Improve Outcomes in Community Practice

Learn about current guidelines and evidence for immunotherapy to treat patients with resectable melanoma, with a focus on the (neo)adjuvant setting for stage IIB/C disease and strategies for integrating these expert recommendations and shared decision-making into your clinical practice through a downloadable living slideset and patient resource toolkit.

Follow this link to find a guide that will help your patients and their families explore common questions about stage II melanoma with you, including therapy eligibility, the pros and cons of adjuvant therapy vs active surveillance, and factors to consider when making treatment decisions.

Share

Program Content

Activities

Resectable Melanoma Care
Driving Improved Outcomes in Resectable Melanoma: Pathways for Optimized Adjuvant Immunotherapy Strategies
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 14, 2024

Expires: October 13, 2025

Faculty

cover img faculity

Jason Luke, MD, FACP

Associate Director for Clinical Research
Director, Immunotherapy and Drug Development Center
Associate Professor of Medicine
UPMC Hillman Cancer Center 
University of Pittsburgh
Pittsburgh, Pennsylvania

cover img faculity

Govind Warrier, MD, MPH

Assistant Professor, Medical Oncology
Melanoma/Skin Cancer and Cancer Immunology Programs
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC, in partnership with AIM at Melanoma Foundation.

Supporters

Supported by an educational grant from Bristol-Myers Squibb.

Bristol Myers Squibb

Partners

AIM at Melanoma Foundation

ProCE Banner